Advair Diskus, Fluticasone/Salmeterol Newswire

Advair Diskus, Fluticasone/Salmeterol Newswire

Comprehensive Real-Time News Feed for Advair Diskus, Fluticasone/Salmeterol (generic).

Results 1 - 20 of 119 in Advair Diskus, Fluticasone/Salmeterol (generic)

  1. Zacks Investment Research Upgrades Mylan N.V. (MYL) to HoldRead the original story w/Photo

    Friday Jun 30 | IntersportsWire

    According to Zacks, "Mylan's EpiPen woes continues as sales of the product declined due to increased competition and entry of generics. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year.

    Comment?

  2. Hikma Shakes Up U.S. Operations After FDA Disappointment; CEO Said Darwazah to Lead GroupRead the original story w/Photo

    Monday Jun 26 | TheStreet.com

    Hikma Pharmaceuticals Plc shares were active in London trading Monday after the drugmaker unveiled a reorganization of its U.S. business that includes a change in leadership. The shakeup of its U.S. business, West Ward Pharmaceuticals , follows a 'complete response letter' issued by the U.S. Food & Drug Administration in May in relation to its crucial Advair Diskus generic application, which the company now says has a low likelihood of it receiving approval in the current year.

    Comment?

  3. Investment Analysts' Recent Ratings Updates for Mylan N.V.Read the original story w/Photo

    Friday Jun 23 | AmericanBankingNews.com

    6/20/2017 - Mylan N.V. was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. According to Zacks, "Mylan's EpiPen woes continues as sales of the product declined due to increased competition and entry of generics.

    Comment?

  4. Mylan N.V. (MYL) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    Thursday Jun 22 | Daily Political

    According to Zacks, "Mylan's EpiPen woes continues as sales of the product declined due to increased competition and entry of generics. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year.

    Comment?

  5. Mylan N.V. (MYL) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Jun 17, 2017 | IntersportsWire

    According to Zacks, "Mylan's first-quarter results beat on earnings but missed the top line due to decline in EpiPen sales as a result of increased competition and entry of generics. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year.

    Comment?

  6. FDA accepts Sandoz regulatory submission for a generic version of Advair DiskusRead the original story

    Jun 15, 2017 | GlobeNewswire

    Holzkirchen, June 15, 2017- Sandoz today announced that the US Food and Drug Administration has accepted its Abbreviated New Drug Application for fluticasone propionate / salmeterol combination product, a substitutable generic version of Advair DiskusA [1]. If approved, the product will treat asthma in patients aged four years and older, in addition to providing maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease .

    Comment?

  7. Mylan (MYL) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    Jun 4, 2017 | IntersportsWire

    According to Zacks, "Mylan's Generics segment has been performing well driven by new product launches. However, EpiPen woes continues as sales of the product declined due to increased competition and entry of generics.

    Comment?

  8. Mylan (MYL) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    May 25, 2017 | AmericanBankingNews.com

    According to Zacks, "Mylan's Generics segment has been performing well driven by new product launches. However, EpiPen woes continues as sales of the product declined due to increased competition and entry of generics.

    Comment?

  9. Investigations 48 mins ago 3:16 p.m.Buying prescriptions from Canada: Is it safe and is it legal?Read the original story

    May 23, 2017 | WBIR-TV Knoxville

    Some call it 'The Canadian Remedy' patients looking to save money on prescriptions by taking their business across our Northern border. There's no way to know how many try but a quick Google search returns dozens of mail order pharmacies claiming to be from Canada, many listing drastically cheaper prices than in the U.S. Gerard Longval has been a pharmacist in Ontario, Canada for more than 30 years, in a town just across the border from Buffalo, NY.

    Comment?

  10. Mining stocks help FTSE swing back to close higher as us jitters easeRead the original story w/Photo

    May 19, 2017 | Sunday Herald

    Bringing you the best journalism, comment and analysis in Scotland, wherever and whenever you need it, in any format. AD-FREE subscriptions now available too.

    Comment?

  11. Eutelsat sells Spanish stake to Abertis, Hikma Pharma Lowers OutlookRead the original story

    May 19, 2017 | Ticker

    Gemfields received 112 million offer from its major investor Pallinghurst. Grainger said first-half profit soared 21%.

    Comment?

  12. European Stocks Gain, Oil Tests One-Month Highs as Risk Sentiment RecoversRead the original story w/Photo

    May 19, 2017 | TheStreet.com

    European stocks rose firmly higher in the opening hour of trading Friday as global financial markets attempted to claw back losses from a volatile week of trading sparked by an escalating political maelstrom that threatens to engulf the White House. The region-wide Stoxx Europe 600 index , the broadest measure of share prices, was marked 0.4% higher at 390.72 points by 09:00 BST, with both financial and industrial stocks leading the advance.

    Comment?

  13. Brazil's President Michel Temer Clings to Power; Emerging Market Stocks StruggleRead the original story w/Photo

    May 19, 2017 | TheStreet.com

    Brazil's embattled President, Michel Temer , defiantly refused to step down amid a corruption probe that has engulfed the government and pummelled financial markets in Latin America's biggest economy. In a televised statement late Thursday, Temer insisted he had done nothing wrong and vowed to remain in power despite a Supreme Court investigation into allegations he bribed witnesses in a far-reaching probe linked to government kickbacks to favored businesses and the ouster of former President Dilma Rouseff .

    Comment?

  14. Hikma updates revenue guidance after US rejects asthma drugRead the original story w/Photo

    May 19, 2017 | Live Charts

    Pharma group Hikma has updated its guidance on full year revenue to be $2bn - $2.1bn in constant currency after last week's rejection of its asthma drug by US regulators. This change reflects changes in the outlook for Hikma's generics business, where it has revised expectations for the launch timing of its generic version of Advair Diskus and where it is experiencing increased price erosion on marketed products.

    Comment?

  15. Hikma Trims Full Year Revenue Guidance After Advair Diskus DelayRead the original story w/Photo

    May 19, 2017 | TheStreet.com

    Hikma Pharmaceuticals plc lowered its full year revenue guidance Friday after the U.S. Food & Drug Administration expressed concern over its generic Advair Diskus product. Hikma said it expects revenues for its current fiscal year to come in at between $2 billion and $2.1 billion, down from the $2.2 billion forecast it published in its recent annual report last month.

    Comment?

  16. London pre-open: Stocks seen higher on positive US cuesRead the original story w/Photo

    May 18, 2017 | Live Charts

    London stocks were set for a firmer open on Friday following a positive session on Wall Street, where shares rebounded from this week's Trump-inspired selloff. The FTSE 100 was expected to open 33 points higher at 7,469.

    Comment?

  17. UPDATE 1-Hikma trims FY revenue forecast on Advair U.S. launch delayRead the original story w/Photo

    Jun 2, 2016 | Reuters

    Shares of the company fell as much 7.47 percent to 1,573 pence, the lowest since May, 2014. They were the top loser on the FTSE 100 bluechip index .FTSE and the pan-European Stoxx 600 index .

    Comment?

  18. Mylan (MYL) - Analysts' Weekly Ratings UpdatesRead the original story w/Photo

    May 18, 2017 | AmericanBankingNews.com

    According to Zacks, "Mylan's first-quarter results beat on earnings but missed the top line due to decline in EpiPen sales as a result of increased competition and entry of generics. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year.

    Comment?

  19. FTSE 100 movers: Fresnillo shines as gold rallies; Hikma slumps on downgradeRead the original story w/Photo

    May 17, 2017 | Live Charts

    London's FTSE 100 was down 0.5% to 7,485.04 in afternoon trade as investors digested the latest round of UK jobs data and political turmoil in the US. Precious metals miner Fresnillo was the standout gainer as gold prices rallied on safe-haven demand amid worries about US President Donald Trump.

    Comment?

  20. Mylan (MYL) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    May 17, 2017 | IntersportsWire

    According to Zacks, "Mylan's first-quarter results beat on earnings but missed the top line due to decline in EpiPen sales as a result of increased competition and entry of generics. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year.

    Comment?